alprostadil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 138 745-65-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alprostadil
  • prostaglandin E1
  • vasaprostan
  • PGE1
  • prostavasin
A potent vasodilator agent that increases peripheral blood flow.
  • Molecular weight: 354.49
  • Formula: C20H34O5
  • CLOGP: 2.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 94.83
  • ALOGS: -3.65
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg P
20 mcg P
0.25 mg urethral

ADMET properties:

PropertyValueReference
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 45.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 1981 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EA01 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Prostaglandins
ATC G04BE01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs used in erectile dysfunction
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:50249 anticoagulant
FDA PE N0000009059 Genitourinary Arterial Vasodilation
FDA EPC N0000175454 Prostaglandin Analog
FDA EPC N0000180189 Prostaglandin E1 Agonist
FDA MoA N0000000106 Prostaglandin Receptor Agonists
FDA Chemical/Ingredient N0000007706 Prostaglandins
FDA PE N0000009911 Venous Vasodilation
MeSH PA D064804 Urological Agents
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Coarctation of aorta indication 7305005
Congenital atresia of tricuspid valve indication 63042009
Tetralogy of Fallot indication 86299006 DOID:6419
Pulmonary artery stenosis indication 95441000
Congenital atresia of the pulmonary valve indication 204342004
Ebstein's anomaly of tricuspid valve indication 204357006 DOID:14289
Impotence indication 397803000
Aorta Dextratransposition with Intact Ventricular Septum indication
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus indication
Pulmonary hypertension off-label use 70995007 DOID:6432
Peripheral vascular disease off-label use 400047006
Apnea contraindication 1023001
Induratio penis plastica contraindication 1335005 DOID:8616
Priapism contraindication 6273006 DOID:9286
Thrombocytosis contraindication 6631009 DOID:2228
Sickle cell trait contraindication 16402000
Disorder of lung contraindication 19829001 DOID:850
Urethritis contraindication 31822004 DOID:1343
Fibrosis of corpus cavernosum contraindication 32608004
Balanitis contraindication 44882003 DOID:13033
Low blood pressure contraindication 45007003
Respiratory distress syndrome in the newborn contraindication 46775006
Blood coagulation disorder contraindication 64779008 DOID:1247
Urethral stricture contraindication 76618002
Leukemia, disease contraindication 93143009 DOID:1240
Multiple myeloma contraindication 109989006 DOID:9538
Penis implantation contraindication 119996002
Hb SS disease contraindication 127040003 DOID:10923
Erythrocytosis contraindication 127062003
Lymphoid leukemia contraindication 188725004 DOID:1037
Pyloric obstruction contraindication 244815007
Penis bent contraindication 249247007
Deformity of Erection of the Penis contraindication
Hypospadia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST EC50 8 WOMBAT-PK CHEMBL
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST EC50 6.80 WOMBAT-PK CHEMBL
Cation channel sperm-associated protein 4 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 3 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 1 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 2 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST EC50 8.80 WOMBAT-PK
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST EC50 9 WOMBAT-PK
Prostaglandin D2 receptor GPCR EC50 7.30 WOMBAT-PK
Prostacyclin receptor GPCR EC50 7.50 WOMBAT-PK
Prostacyclin receptor Unclassified AGONIST Ki 7.50 IUPHAR
Prostaglandin E2 receptor EP1 subtype Unclassified AGONIST Ki 7 IUPHAR
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST Ki 8 IUPHAR
Prostaglandin E2 receptor EP2 subtype GPCR Ki 7.66 CHEMBL
Prostaglandin E2 receptor EP1 subtype GPCR Ki 8.22 CHEMBL
Prostaglandin E2 receptor EP3 subtype GPCR Ki 8.30 CHEMBL
Prostaglandin E2 receptor EP3 subtype Unclassified AGONIST EC50 9.35 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR Ki 8.51 CHEMBL
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 9.20 IUPHAR

External reference:

IDSource
D000527 MESH_DESCRIPTOR_UI
4018099 VUID
N0000146437 NUI
C0002335 UMLSCUI
D00180 KEGG_DRUG
48988008 SNOMEDCT_US
109119001 SNOMEDCT_US
11600 MMSL
598 RXNORM
4154 MMSL
d01387 MMSL
4018099 VANDF
000704 NDDF
CHEMBL495 ChEMBL_ID
DB00770 DRUGBANK_ID
F5TD010360 UNII
4425 INN_ID
XPG PDB_CHEM_ID
CHEBI:15544 CHEBI
5280723 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PROSTIN HUMAN PRESCRIPTION DRUG LABEL 1 0009-3169 INJECTION, SOLUTION 500 ug INTRAVENOUS NDA 13 sections
Caverject HUMAN PRESCRIPTION DRUG LABEL 1 0009-3701 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20.50 ug INTRACAVERNOUS NDA 19 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 0009-5181 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 ug INTRACAVERNOUS NDA 20 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 0009-5182 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 ug INTRACAVERNOUS NDA 20 sections
Caverject HUMAN PRESCRIPTION DRUG LABEL 1 0009-7686 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 41.10 ug INTRACAVERNOUS NDA 19 sections
MUSE HUMAN PRESCRIPTION DRUG LABEL 1 0037-8110 SUPPOSITORY 125 ug URETHRAL NDA 14 sections
MUSE HUMAN PRESCRIPTION DRUG LABEL 1 0037-8120 SUPPOSITORY 250 ug URETHRAL NDA 14 sections
MUSE HUMAN PRESCRIPTION DRUG LABEL 1 0037-8130 SUPPOSITORY 500 ug URETHRAL NDA 14 sections
MUSE HUMAN PRESCRIPTION DRUG LABEL 1 0037-8140 SUPPOSITORY 1000 ug URETHRAL NDA 14 sections
Alprostadil HUMAN PRESCRIPTION DRUG LABEL 1 0703-1501 INJECTION, SOLUTION, CONCENTRATE 500 ug INTRAVASCULAR ANDA 12 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-010 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 ug INTRACAVERNOUS NDA 13 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-020 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 ug INTRACAVERNOUS NDA 13 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-040 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 ug INTRACAVERNOUS NDA 13 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 63539-121 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 ug INTRACAVERNOUS NDA 20 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 63539-221 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 ug INTRACAVERNOUS NDA 20 sections